PulseExploreJournal ClubTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 4037: Pharmacological inhibition of eIF4A1 suppresses leukemogenesis via specifically rewiring amino acid biosynthesis

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXu Hannah ZhangHZH ZhangLDLei Dong

Discussion

Loading...

Member takes

Overview

Demonstrates that eIF4A1 inhibition suppresses leukemogenesis in AML, suggesting it may be a novel therapeutic target.

Key Points

  • The aim is to investigate eIF4A1 as a critical factor in AML and its potential as a therapeutic target.
  • Multi-omics analysis to assess eIF4A1 expression in AML cells and patient samples.
  • Genetic depletion and pharmacological inhibition of eIF4A1 to evaluate effects on AML progression.
  • BioID-MS assays, PLA, and co-IP assays to explore the interaction between eIF4A1 and YB-1.
  • Isotope tracing for metabolic profiling assessing serine metabolism and PHGDH function.
  • CLIP-qPCR to verify eIF4A1 and YB-1 binding to PHGDH mRNA.
  • eIF4A1 expression is significantly higher in AML cells than in healthy controls.
  • eIF4A1 knockout impairs AML cell growth and delays disease progression in mouse models.
  • Zotatifin, an eIF4A1 inhibitor, reduces leukemia burden and extends survival in mouse models.
  • The combination of Zotatifin and YB-1 inhibitor shows strong synergistic effects in eradicating AML.
  • eIF4A1 operates through an eIF4F-independent mechanism, crucially impacting amino acid biosynthesis.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd13a79560c99a0a2e42https://doi.org/10.1158/1538-7445.am2026-4037
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Redefining eIF4E's function in Acute Myeloid Leukemia: Implications for engraftment and survival2025
  2. 2Abstract A028: Targeting eIF4A1 reveals crosstalk between BCR signaling and translation in aggressive B-cell lymphoma2026
  3. 3Abstract B007: Unexpected synthetic lethality mechanisms in eIF4A-targeted therapy2024
  4. 4Abstract 272: Novel role for eIF4E in homing of acute myeloid leukemia cells2024
  5. 5Abstract 658: Small molecule allosteric regulators of eIF4E activity target proteomic dysregulation and demonstrate potent antiproliferative activity in multiple myeloma models whilst sparing normal immune cells2024